Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States

Hailey J. Park, Gregg S. Gonsalves, Sophia T. Tan, J. Daniel Kelly, George W. Rutherford, Robert M. Wachter, Robert Schechter, A. David Paltiel and Nathan C. Lo ()
Additional contact information
Hailey J. Park: Stanford University
Gregg S. Gonsalves: Yale School of Public Health
Sophia T. Tan: Stanford University
J. Daniel Kelly: University of California, San Francisco
George W. Rutherford: University of California, San Francisco
Robert M. Wachter: University of California, San Francisco
Robert Schechter: California Department of Public Health
A. David Paltiel: Yale School of Public Health
Nathan C. Lo: Stanford University

Nature Communications, 2024, vol. 15, issue 1, 1-10

Abstract: Abstract There is a public health need to understand how different frequencies of COVID-19 booster vaccines may mitigate the risk of severe COVID-19, while accounting for waning of protection and differential risk by age and immune status. By analyzing United States COVID-19 surveillance and seroprevalence data in a microsimulation model, here we show that more frequent COVID-19 booster vaccination (every 6–12 months) in older age groups and the immunocompromised population would effectively reduce the burden of severe COVID-19, while frequent boosters in the younger population may only provide modest benefit against severe disease. In persons 75+ years, the model estimated that annual boosters would reduce absolute annual risk of severe COVID-19 by 199 (uncertainty interval: 183–232) cases per 100,000 persons, compared to a one-time booster vaccination. In contrast, for persons 18–49 years, the model estimated that annual boosters would reduce this risk by 14 (10–19) cases per 100,000 persons. Those with prior infection had lower benefit of more frequent boosting, and immunocompromised persons had larger benefit. Scenarios with emerging variants with immune evasion increased the benefit of more frequent variant-targeted boosters. This study underscores the benefit of considering key risk factors to inform frequency of COVID-19 booster vaccines in public health guidance and ensuring at least annual boosters in high-risk populations.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-024-45549-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45549-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-45549-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().